Gastric Cancer

22 competing products in clinical development for Gastric Cancer.

Pipeline by Phase

Pre-clinical1

Phase 12

Phase 1/22

Phase 27

Phase 2/31

Phase 39

All Products (22)

Product	Company	Stage	Status	Hype
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + Chemotherapy	Daiichi Sankyo	Phase 3	Recruiting	47
ONO-4538 + Ipilimumab + Oxaliplatin + Capecitabine + S-1	Ono Pharmaceutical	Phase 3	Active	44
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + Rilvegostomig	Daiichi Sankyo	Phase 2	Recruiting	42
Trastuzumab + Fluorouracil + Cisplatin + Capecitabine	Chugai Pharmaceutical	Phase 3	Completed	40
S-1 + Oxaliplatin + Cisplatin	Sun Pharmaceutical	Phase 3	Completed	40
ONO-4538 + Placebo	Ono Pharmaceutical	Phase 3	Completed	40
Nivolumab + Ipilimumab + Oxaliplatin + Capecitabine + Leucovorin + Fluorouracil	Ono Pharmaceutical	Phase 3	Completed	40
Nivolumab + Tegafur-gimeracil-oteracil potassium + Oxaliplatin + Capecitabine + Placebo	Ono Pharmaceutical	Phase 3	Completed	40
ONO-4578 + Oxaliplatin + Capecitabine + S-1 + Nivolumab + Placebo	Ono Pharmaceutical	Phase 2	Active	39
ONO-4538 + Oxaliplatin + Tegafur- Gimeracil-Oteracil potassium + Capecitabine + Placebo	Ono Pharmaceutical	Phase 2/3	Completed	38
Ramucirumab	Eli Lilly	Phase 2	Completed	35
S-1 + LV	Sun Pharmaceutical	Phase 2	Completed	35
ARQ 197	Kyowa Kirin	Phase 2	Completed	35
Irinotecan + Nimotuzumab	Daiichi Sankyo	Phase 3	Terminated	32
S-1 for 6 months + S-1 for 1 year	Sun Pharmaceutical	Phase 3	Withdrawn	32
Ramucirumab + Nivolumab	Ono Pharmaceutical	Phase 1/2	Completed	32
Ramucirumab + MEDI4736	Eli Lilly	Phase 1	Completed	29
Mogamulizumab + Nivolumab	Kyowa Kirin	Phase 1	Completed	29
Zolbetuximab	Astellas Pharma	Pre-clinical	Completed	26
E7070	Eisai	Phase 1/2	Terminated	24
Infigratinib	LianBio	Phase 2	UNKNOWN	21
Infigratinib	LianBio	Phase 2	Terminated	17